These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 10195641)

  • 1. The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines.
    Wilson AD; Lövgren-Bengtsson K; Villacres-Ericsson M; Morein B; Morgan AJ
    Vaccine; 1999 Mar; 17(9-10):1282-90. PubMed ID: 10195641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Quillaja saponaria triterpenoid content on the immunomodulatory capacity of Epstein-Barr virus iscoms.
    Dotsika E; Karagouni E; Sundquist B; Morein B; Morgan A; Villacres-Eriksson M
    Scand J Immunol; 1997 Mar; 45(3):261-8. PubMed ID: 9122615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector.
    Finerty S; Tarlton J; Mackett M; Conway M; Arrand JR; Watkins PE; Morgan AJ
    J Gen Virol; 1992 Feb; 73 ( Pt 2)():449-53. PubMed ID: 1311367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro T cell responses to a candidate Epstein-Barr virus vaccine: human CD4+ T cell clones specific for the major envelope glycoprotein gp340.
    Ulaeto D; Wallace L; Morgan A; Morein B; Rickinson AB
    Eur J Immunol; 1988 Nov; 18(11):1689-97. PubMed ID: 2904885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin.
    Ragot T; Finerty S; Watkins PE; Perricaudet M; Morgan AJ
    J Gen Virol; 1993 Mar; 74 ( Pt 3)():501-7. PubMed ID: 8383183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virus-specific cytotoxic T cell responses are associated with immunity of the cottontop tamarin to Epstein-Barr virus (EBV).
    Wilson AD; Shooshstari M; Finerty S; Watkins P; Morgan AJ
    Clin Exp Immunol; 1996 Feb; 103(2):199-205. PubMed ID: 8565300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization of cottontop tamarins and rabbits with a candidate vaccine against the Epstein-Barr virus based on the major viral envelope glycoprotein gp340 and alum.
    Finerty S; Mackett M; Arrand JR; Watkins PE; Tarlton J; Morgan AJ
    Vaccine; 1994 Oct; 12(13):1180-4. PubMed ID: 7839721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of two T-cell epitopes on the candidate Epstein-Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones.
    Wallace LE; Wright J; Ulaeto DO; Morgan AJ; Rickinson AB
    J Virol; 1991 Jul; 65(7):3821-8. PubMed ID: 1710291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MHC class II-restricted presentation of endogenously synthesized antigen: Epstein-Barr virus transformed B cell lines can present the viral glycoprotein gp340 by two distinct pathways.
    Lee SP; Wallace LE; Mackett M; Arrand JR; Searle PF; Rowe M; Rickinson AB
    Int Immunol; 1993 May; 5(5):451-60. PubMed ID: 8391306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recognition of autologous lymphoblastoid cells by cloned human T cells: inhibition of cytotoxicity by anti-HLA antibody but not by antibody to Epstein-Barr virus induced cell surface antigen.
    Hank JA; Sondel PM
    Hum Immunol; 1984 Apr; 9(4):211-9. PubMed ID: 6201468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
    Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
    J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
    Hill AB; Lee SP; Haurum JS; Murray N; Yao QY; Rowe M; Signoret N; Rickinson AB; McMichael AJ
    J Exp Med; 1995 Jun; 181(6):2221-8. PubMed ID: 7539044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes.
    Morgan AJ; Finerty S; Lovgren K; Scullion FT; Morein B
    J Gen Virol; 1988 Aug; 69 ( Pt 8)():2093-6. PubMed ID: 2841417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro cytokine production and growth inhibition of lymphoblastoid cell lines by CD4+ T cells from Epstein-Barr virus (EBV) seropositive donors.
    Wilson AD; Hopkins JC; Morgan AJ
    Clin Exp Immunol; 2001 Oct; 126(1):101-10. PubMed ID: 11678905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping of B-cell epitopes on the polypeptide chain of the Epstein-Barr virus major envelope glycoprotein and candidate vaccine molecule gp340.
    Pither RJ; Zhang CX; Shiels C; Tarlton J; Finerty S; Morgan AJ
    J Virol; 1992 Feb; 66(2):1246-51. PubMed ID: 1370550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens.
    Yang J; Lemas VM; Flinn IW; Krone C; Ambinder RF
    Blood; 2000 Jan; 95(1):241-8. PubMed ID: 10607708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution of epitopes within the amino acid sequence of the Epstein-Barr virus major envelope glycoprotein, gp340, recognized by hyperimmune rabbit sera.
    Pither RJ; Nolan L; Tarlton J; Walford J; Morgan AJ
    J Gen Virol; 1992 Jun; 73 ( Pt 6)():1409-15. PubMed ID: 1376768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salivary and serum IgA antibodies to the Epstein-Barr virus glycoprotein gp340: incidence and potential for virus neutralization.
    Yao QY; Rowe M; Morgan AJ; Sam CK; Prasad U; Dang H; Zeng Y; Rickinson AB
    Int J Cancer; 1991 Apr; 48(1):45-50. PubMed ID: 1850382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas.
    Morgan AJ; Mackett M; Finerty S; Arrand JR; Scullion FT; Epstein MA
    J Med Virol; 1988 Jun; 25(2):189-95. PubMed ID: 2839612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals.
    Metes D; Storkus W; Zeevi A; Patterson K; Logar A; Rowe D; Nalesnik MA; Fung JJ; Rao AS
    Transplantation; 2000 Nov; 70(10):1507-15. PubMed ID: 11118098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.